Thomas Hawes

Tom holds a bachelor's degree in Philosophy from Brigham Young University, an MD from New York Medical College, and an MBA from Harvard Business School.

Dr. Tom Hawes joined Sandbox in 2008 and is a Founder of Sandbox Clinical Ventures and a Managing Director of the Blue Venture Funds. He currently serves on the board of directors of Humata Health, Octave Bioscience, and Upward Health and is a board observer of PinkDx, Big Health, and Onc.AI. Dr. Hawes previously served as a board member of AbleTo (acquired by Optum), HeartFlow (NASDAQ: HTFL), InVivoLink (acquired by HCA), PatientCo (acquired by WayStar), Nexidia (acquired by NICE), OncoHealth (acquired by Arsenal Capital Partners and McKesson), Phreesia (NYSE: PHR), ID Experts (NASDAQ: ZFOX), Owl Health (acquired by NeuroFlow), First Dollar (acquired by Inspira), Healthify (acquired by Wellsky), and Verata Health (acquired by Olive.Ai), and as a board observer of Thrive

Earlier Detection (NASDAQ: EXAS).

​

Prior to Sandbox, Dr. Hawes matched at Yale School of Medicine for residency. During his medical training, he worked on clinical studies at the ISK Institute

for Orthopedics and Sports Medicine and on outcomes research at the National Cancer Institute and New York Medical College’s Cardiothoracic Surgery

Department.

​

Dr. Hawes holds an MD from New York Medical College, an MBA from Harvard Business School, and a BA from Brigham Young University. He is also a

Kauffman Fellow.

Tom served his fellowship under the mentorship of Matt Downs, a Managing Director of Sandbox Industries. He graduated as a member of Class 15.